Table 2.
Summary of FOLFIRINOX Treatment
| Variable | Value |
|---|---|
| Total cycle | 7 (4–14) |
| Dose reduction | 71 (60.7) |
| Dose reduction at start | 48 (41.0) |
| Dose reduction after 1st cycle | 23 (19.7) |
| Best response | |
| CR | 1 (0.9) |
| PR | 31 (26.5) |
| SD | 74 (63.2) |
| PD | 5 (4.3) |
| NA | 6 (5.1) |
| RR (CR+PR) | 32 (27.4) |
| DCR (CR+PR+SD) | 106 (90.6) |
| Serum CA 19-9 lowest, U/mL | 51.6 (11.0–290.5) |
| Resection after FOLFIRINOX | 29 (24.8) |
| R0 | 21/29 (72.4) |
| R1 | 8/29 (27.6) |
| Grade 3 and 4 toxicity | 89 (76.1) |
| Hematologic | |
| Neutropenia | 73 (62.4) |
| Febrile neutropenia | 7 (6.0) |
| Thrombocytopenia | 13 (11.1) |
| Anemia | 15 (12.8) |
| Non-hematologic | |
| Nausea and vomiting | 23 (19.7) |
| Diarrhea | 5 (4.3) |
| Hypersensitivity | 1 (0.9) |
| Mucositis | 3 (2.6) |
Data are presented as median (interquartile range) or number (%).
CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; NA, not assessed; RR, response rate; DCR, disease control rate; CA 19-9, carbohydrate antigen 19-9.